3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adrenocortical Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Capecitabine
35
Oxaliplatin
32
Fluorouracil
29
Leucovorin
26
Irinotecan
22
Bevacizumab
19
Cetuximab
17
Radiotherapy
16
Radiation
11
Surgical Procedures, Operative
6
Radiotherapy, Intensity-Modulated
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
Celecoxib
5
Neoadjuvant Therapy
4
Immunohistochemistry
4
Biopsy
4
Amplified Fragment Length Polymorphism Analysis
4
cediranib
3
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Folfox protocol
3
Drug Therapy
3
Cisplatin
3
sargramostim
2
regorafenib
2
pembrolizumab
2
fludarabine phosphate
2
aldesleukin
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Rectal Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts